Clinical Trial Update: Therapeutic Response of Sodium-glucose Co-transporter Type-2 Inhibitor in Non-diabetic MAFLD Patients: a Pilot Study [Phase 4]

View source ↗

Summary

A Phase 4 pilot study is assessing the therapeutic response of an SGLT2 inhibitor in non-diabetic patients with Metabolic Associated Fatty Liver Disease; the tr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Metabolic-associated Fatty Liver Disease

Drugs mentioned

• SGLT2 inhibitor

Snippet

Sponsor: Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation | Conditions: Metabolic Associated Fatty Liver Disease | Phase 4 | Status: ACTIVE_NOT_RECRUITING